Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clobazam.

Yu-tze Ng1, Stephen D Collins

  • 1Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013-4496, USA.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures.

Annals of clinical and translational neurology·2024
Same author

Refractory Jeavons Syndrome from Birth Symptomatic to PLCB1 Mutation.

Child neurology open·2023
Same author

Maximizing Quality of Life in Children with Epilepsy.

Children (Basel, Switzerland)·2023
Same author

Neonatal Epileptic Encephalopathies.

Seminars in pediatric neurology·2021
Same author

Targeted interleukin-10 plasmid DNA therapy in the treatment of osteoarthritis: Toxicology and pain efficacy assessments.

Brain, behavior, and immunity·2020
Same author

Transient Corpus Callosal Lesion Presenting with Alien Hand Syndrome.

Pediatric neurology·2018
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Brain interstitial fluid pharmacokinetics and therapeutic effect of a BBB penetrating amyloid beta antibody measured by microdialysis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Clobazam shows promise for treating severe childhood epilepsies like Lennox-Gastaut syndrome (LGS). Early use may improve seizure control and reduce adverse effects in patients with refractory epilepsy.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Catastrophic childhood epilepsies, including infantile spasms (IS) and Lennox-Gastaut syndrome (LGS), are severe and often persist into adulthood.
  • Effective management aims to maximize seizure control while minimizing adverse effects, particularly cognitive and behavioral issues.

Purpose of the Study:

  • To review the use of clobazam in epilepsy treatment, focusing on its potential benefits for Lennox-Gastaut syndrome (LGS).
  • To explore clobazam's efficacy and safety as an adjunctive therapy for refractory epilepsy, specifically LGS.

Main Methods:

  • Review of European studies involving over 3000 pediatric and adult epilepsy patients, including 300 with LGS.
  • Investigation of clobazam's safety and efficacy in a Phase 2 study for LGS patients.

Related Experiment Videos

Main Results:

  • Clobazam has demonstrated clinical benefit and a safe administration profile in extensive European studies.
  • Data from over 3000 patients indicate positive outcomes, with 300 diagnosed with LGS.

Conclusions:

  • Clobazam is being investigated in the U.S. for refractory epilepsy, particularly LGS.
  • A Phase 2 study is evaluating clobazam as adjunctive therapy for LGS, aiming for FDA approval.